| Literature DB >> 32370153 |
Asif Naeem1, Maaweya E Hamed2, Majed F Alghoribi3, Waleed Aljabr1, Hadel Alsaran1, Mushira A Enani4, Bandar Alosaimi1,5.
Abstract
The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a lethal zoonotic pathogen circulating in the Arabian Peninsula since 2012. There is no vaccine for MERS and anti-viral treatment is generally not applicable. We investigated the evolution of the MERS-CoV spike gene sequences and changes in viral loads over time from patients in Saudi Arabia from 2105-2017. All the MERS-CoV strains belonged to lineage 5, and showed high sequence homology (99.9%) to 2017 strains. Recombination analysis showed a potential recombination event in study strains from patients in Saudi Arabia. The spike gene showed eight amino acid substitutions, especially between the A1 and B5 lineage, and contained positively selected codon 1020. We also determined that the viral loads were significantly (p < 0.001) higher in fatal cases, and virus shedding was prolonged in some fatal cases beyond 21 days. The viral concentration peaked during the first week of illness, and the lower respiratory specimens had higher levels of MERS-CoV RNA. The presence of the diversifying selection and the topologies with the structural mapping of residues under purifying selection suggested that codon 1020 might have a role in the evolution of spike gene during the divergence of different lineages. This study will im-prove our understanding of the evolution of MERS-CoV, and also highlights the need for enhanced surveillance in humans and dromedaries. The presence of amino acid changes at the N-terminal domain and structural mapping of residues under positive selection at heptad repeat 1 provides better insight into the adaptive evolution of the spike gene and might have a potential role in virus-host tropism and pathogenesis.Entities:
Keywords: Evolution; Middle East Respiratory Syndrome Coronavirus; Spike Gene; Viral Load
Year: 2020 PMID: 32370153 PMCID: PMC7290774 DOI: 10.3390/v12050502
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Clinical and epidemiological profile of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) cases.
| Patient No. | Sample No. | Gender | Age | Specimen Type * | Onset Date | Date of Sample Collection | E-Gene Ct | Orf1a Ct | Health-Care Worker | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | Female | 57 | NPA | 20-Sep-15 | 23-Sep-15 | 37 | 35 | NO | Recovered |
| 2 | Female | 57 | NPA | 20-Sep-15 | 24-Sep-15 | 34 | 35 | |||
| 3 ** | Female | 57 | NPA | 20-Sep-15 | 28-Sep-15 | 30 | 30 | |||
| 4 | Female | 57 | NPA | 20-Sep-15 | 29-Sep-15 | 35 | 36 | |||
| 2 | 1 | Female | 59 | NPA | 30-Aug-15 | 23-Sep-15 | 35 | 36 | NO | Died |
| 2 ** | Female | 59 | NPA | 30-Aug-15 | 28-Sep-15 | 32 | 32 | |||
| 3 | Female | 59 | NPA | 30-Aug-15 | 29-Sep-15 | 34 | 33 | |||
| 4 | Female | 59 | NPA | 30-Aug-15 | 01-Oct-15 | 35 | 36 | |||
| 3 | 1 ** | Male | 57 | NPA | 10-Sep-15 | 29-Sep-15 | 33 | 33 | NO | Died |
| 2 | Male | 57 | NPA | 10-Sep-15 | 01-Oct-15 | 37 | 37 | |||
| 4 | 1 | Female | 75 | NPA | 12-Sep-15 | 30-Sep-15 | 30 | 30 | NO | Died |
| 2 ** | Female | 75 | NPA | 12-Sep-15 | 02-Oct-15 | 28 | 29 | |||
| 5 | 1 | Male | 26 | NPA | 30-Jun-16 | 02-Jul-16 | 25 | 26 | NO | Died |
| 2 ** | Male | 26 | NPA | 30-Jun-16 | 04-Jul-16 | 22 | 22 | |||
| 6 | 1 ** | Male | 26 | NPA | 04-Jun-17 | 07-Jun-17 | 26 | 26 | YES | Recovered |
| 2 | Male | 26 | NPA | 04-Jun-17 | 16-Jun-17 | 34 | 36 | |||
| 3 | Male | 26 | NPA | 04-Jun-17 | 19-Jun-17 | 30 | 30 | |||
| 4 | Male | 26 | NPA | 04-Jun-17 | 23-Jun-17 | 27 | 27 | |||
| 5 | Male | 26 | NPA | 04-Jun-17 | 25-Jun-17 | 26 | 27 | |||
| 7 | 1 ** | Female | 27 | NPA | 08-Jun-17 | 08-Jun-17 | 27 | 27 | YES | Recovered |
| 2 | Female | 27 | NPA | 08-Jun-17 | 13-Jun-17 | 30 | 30 | |||
| 3 | Female | 27 | NPA | 08-Jun-17 | 16-Jun-17 | 31 | 31 | |||
| 8 | 1 | Male | 39 | NPA | 11-Jun-17 | 11-Jun-17 | 30 | 31 | YES | Recovered |
| 2 | Male | 39 | NPA | 11-Jun-17 | 16-Jun-17 | 34 | 34 | |||
| 3 ** | Male | 39 | NPA | 11-Jun-17 | 19-Jun-17 | 27 | 27 | |||
| 4 | Male | 39 | NPA | 11-Jun-17 | 25-Jun-17 | 30 | 32 | |||
| 5 | Male | 39 | NPA | 11-Jun-17 | 29-Jun-17 | 32 | 32 | |||
| 6 | Male | 39 | NPA | 11-Jun-17 | 03-Jul-17 | 34 | 35 | |||
| 9 | 1 ** | Female | 35 | NPA | 31-May-17 | 13-Jun-17 | 26 | 26 | YES | Recovered |
| 2 | Female | 35 | NPA | 31-May-17 | 16-Jun-17 | 32 | 32 | |||
| 3 | Female | 35 | NPA | 31-May-17 | 19-Jun-17 | 29 | 30 | |||
| 4 | Female | 35 | NPA | 31-May-17 | 23-Jun-17 | 33 | 33 | |||
| 10 | 1 ** | Male | 39 | NPA | 16-Jun-17 | 19-Jun-17 | 25 | 25 | NO | Recovered |
| 2 | Male | 39 | NPA | 16-Jun-17 | 27-Jun-17 | 33 | 34 | |||
| 11 | 1 ** | Male | 75 | TA | 22-Jun-17 | 23-Jun-17 | 15 | 15 | NO | Died |
| 2 | Male | 75 | TA | 22-Jun-17 | 24-Jun-17 | 15 | 15 | |||
| 12 | 1 | Male | 77 | NPA | 05-Oct-17 | 08-Oct-17 | 34 | 35 | NO | Recovered |
| 2 ** | Male | 77 | NPA | 05-Oct-17 | 11-Oct-17 | 26 | 26 | |||
| 13 | 1 ** | Female | 75 | NPA | 07-Nov-17 | 12-Nov-17 | 25 | 25 | NO | Died |
| 2 | Female | 75 | NPA | 07-Nov-17 | 16-Nov-17 | 34 | 35 |
* Nasopharyngeal Aspirate (NPA) and/or Tracheal Aspirate (TA); ** Samples with lowest Ct-value or highest RNA copy number were used for sequencing.
Figure 1The maximum likelihood phylogenetic tree based on S gene sequences of 160 MERS-CoV strains is shown. The TN93 + G substitution model was used to generate the S gene tree. Representative strains for clade A are shown in the Figure 1A. Clade b is split into three sections (A–C) for better Lineage 5 is enlarged with annotations to clarify the relationship of the present study strains (B). Bootstrap values in percentage are shown next to the branches. The scale bar indicates the number of nucleotide substitutions per site. Selected MERS-CoV strains were annotated. The 13 MERS-CoV strains from the present study are indicated in black circles (B).
Comparison of the S gene sequence variants of the MERS-CoV isolates from the patients in Saudi Arabia, 2015–2017, and reference strains.
| S1 Subunit | S2 Subunit | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NTD | RBD | HR | ||||||||||||||
| MERS-CoV Strains | 32 | 95 | 126 | 200 | 222 | 228 | 473 | 556 | 588 | 700 | 710 | 745 | 848 | 1020 | 1224 | 1267 |
| JX869059-England-2012/06/13 * | E | T | S | S | N | F | F | A | L | R | P | L | N | Q | G | L |
| MN735680-Saudi Arabia-14-2016 | R | |||||||||||||||
| MN735679-Saudi Arabia-03-2015 | A | R | ||||||||||||||
| MN735681-Saudi Arabia-81-2017 | R | |||||||||||||||
| MN735682-Saudi Arabia-109-2017 | D | R | ||||||||||||||
| MK858156-Saudi Arabia-19-2016 | R | |||||||||||||||
| MK858157-Saudi Arabia-24-2016 | L | R | ||||||||||||||
| MK858158-Saudi Arabia-26-2016 | R | |||||||||||||||
| MK858159-Saudi Arabia-30-2016 | Y | R | ||||||||||||||
| MK858160-Saudi Arabia-37-2017 | A | L | F | R | ||||||||||||
| MK858161-Saudi Arabia-40-2017 | A | L | F | R | ||||||||||||
| MK858162-Saudi Arabia-41-2017 | A | L | F | R | ||||||||||||
| MK858163-Saudi Arabia-42-2017 | R | |||||||||||||||
| MK858164-Saudi Arabia-44-2017 | R | S | ||||||||||||||
| KT806006-Saudi Arabia-2015 * | Y | V | R | S | ||||||||||||
| KT805971-Saudi Arabia-2015 * | A | R | ||||||||||||||
| MG011342-Saudi Arabia-2016 * | I | I | H | R | ||||||||||||
| MG912606-Saudi Arabia-2017 * | A | L | S | F | R | |||||||||||
* Amino acid changes in the study sequences compared to the prototype sequences are shaded in gray. Amino acid abbreviations: Glutamic acid (E); Alanine (A); Threonine (T); Isoleucine (I); Serine (S); Tyrosine (Y); Asparagine (N); Phenylalanine (F); Leucine (L); Arginine (R); Proline (P); Aspartic acid (D); Glutamine (Q); Glycine (G).
Figure 2Results of recombination analysis using genetic algorithm for recombination detection (GARD) in the Datamonkey web server. The red arrow indicates a significant breakpoint that was detected (p-value < 0.05). The x-axis represents the nucleotide site. The two recombinant fragments are presented in the green and blue bars.
Figure 3Functional domains and structural view of amino acid substitutions in the S gene of Middle East Respiratory Syndrome Coronavirus (MERS-CoV). (A) Ribbon representation of the MERS-CoV S gene with amino acid substitutions shown in red spheres with resolved structure in protein database identification (PDB ID: 5 × 59); (B) Surface representation of the S protomer in the Chain A side view showing known glycosylation sites in yellow with amino acid substitutions in red color (PDB ID: 5 × 59); (C) Cartoon representation of all the S protomer for detailed architecture with amino acid changes shown in red spheres; NTD, N-terminal domain; RBD, receptor-binding domain; HR, heptad repeat; CH, central helix (PDB ID: 5 × 59); (D) Ribbon representation of HR region of S protomer; Amino acid changes Q1020R and L1267S are shown in red color (PDB ID: 4MOD); (E) Structural mapping of residue 1020 in the form of inter and intra-helical interactions. The top box shows the interactions for the glutamine residue (Q1020), and the lower box shows the arginine residue (R1020). Hydrogens were removed for a better view. The figures were produced using PyMOL.
Figure 4Changes in MERS-CoV viral RNA concentrations in respiratory samples over time in 13 patients. Estimated viral loads in respiratory tract specimens collected from hospitalized MERS-CoV patients, Saudi Arabia, 1 September 2015–16 November 2017. Patient numbers with an asterisk indicate the fatality. The RNA copies of MERS-CoV in a throat swab or tracheal aspirate were estimated by means of a standard curve in the upstream of envelop (upE) real-time reverse-transcriptase polymerase chain reaction. Different color–symbol combinations denote individual patients; data points below the limit of detection are shown at different levels for clarity.